Genelux (GNLX)

• Market cap: $78.4M
• 1 day: 3.65%
• 5 days: -3.40%
• 1 month: -8.84%
• 3 months: 2.25%
• 6 months: -0.44%
• Year to date: -84.71%
• 1 year: -82.95%
• 5 years: -63.09%
• 10 years: -63.09%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Employees: 25

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

5.75% less ownership

Funds ownership: 20.89% [Q2] → 15.14% (-5.75%) [Q3]

12% less capital invested

Capital invested by funds: $14.1M [Q2] → $12.4M (-$1.76M) [Q3]

23% less funds holding

Funds holding: 73 [Q2] → 56 (-17) [Q3]

81% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 21

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 252% upside
• Avg. target: $19 737% upside
• High target: $30 1,222% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar 17% 1-year accuracy 26 / 150 met price target	1,222% upside $30	Buy Maintained	15 Nov 2024
Guggenheim Kelsey Goodwin 0% 1-year accuracy 0 / 4 met price target	252% upside $8	Buy Initiated	29 Oct 2024